Cytokinetics, Incorporated (CYTK) Guidance & Earnings Results
On 2026-02-24 Cytokinetics, Incorporated raised guidance: "2026 financial guidance provided; cash position ~$1.2B supports commercial…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CYTKCytokinetics, IncorporatedFollow CYTK — free
—
Price chart with a free account
- Market cap
- 8.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 24 Feb 26 | Raised | 2026 financial guidance provided; cash position ~$1.2B supports commercial plans · full year |
Cytokinetics, Incorporated — questions
- What guidance did Cytokinetics, Incorporated give?
- On 2026-02-24: "2026 financial guidance provided; cash position ~$1.2B supports commercial plans"
- When does Cytokinetics, Incorporated report earnings?
- Cytokinetics, Incorporated's next earnings report is expected on 2026-11-04.
Every figure on this page comes from Cytokinetics, Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.